spacer
home > > spring 2009 > the laws of attraction
PUBLICATIONS


The Laws of Attraction

The most challenging bottleneck for nearly every clinical trial is the recruitment of the intended number of patients within the planned timeframe. The selection of the best study sites is therefore of crucial importance to the success of a clinical trial. In order to find a suitable site, it is necessary to understand the motivation to participate. These motivations can include:

  • Scientific interest in a new therapy option: this is a very frequent reason to participate in clinical trials, especially for university hospitals and other scientific oriented organisations
  • The possibility to offer clinical studies to the patients: centres for specific indications and severe diseases are expected to be able to provide the option to participate in clinical trials to their patients
  • Strong relation to the sponsor: if an investigator has already been involved in early stages of the clinical development, they are certainly likely to be interested in participating in later phase clinical studies
  • Financial interests: especially for clinical studies with substances that are not in the frontline of scientific interest, the fee for the treatment of patients within a study may be a motivator for participation in a clinical trial

Good sites combine as many of the above-mentioned motivations as possible.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Michael Sigmund is Managing Director of SSS International Clinical Research, which provides CRO services to the pharmaceutical and biotech industry. Michael has about 20 years’ experience in the field of clinical research. After studying veterinary medicine, he received his DVM in 1988 from the University of Munich. He then joined the pharmaceutical industry and held several positions within biotech and contract research companies. Michael has ample experience in setting up and running clinical trials in European countries. His main interest lies in steamlining information concerning clinical trials to allow easy and effective access to relevant status information for all  parties involved. Michael helped to develop SSS’s professional web-based study information system (SIS).

spacer
Michael Sigmund
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement